Current guidelines in the management of chronic heart failure: Practical issues in their application to the community population

European Journal of Heart Failure

Volumn 7, Issue 3 SPEC. ISS., 2005, Pages 317-321

  McDonald, Ken ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Guidelines; Heart failure; Management

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; METOPROLOL; NITRIC ACID DERIVATIVE; SPIRONOLACTONE;

CLINICAL TRIAL; COMMUNITY; COMORBIDITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART FAILURE, CONGESTIVE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES; RESEARCH DESIGN;

EID: 13844277136     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2005.01.013     Document Type: Review

References (34)

1. CIBIS-II Investigators and Committees The cardiac insufficiency bisoprolol Study II (CIBIS II): a randomised trial Lancet 353 1999 9 13
2. M. Packer for the Carvedilol Prospective Randomised Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure N. Engl. J. Med. 344 2001 1651 16518
3. A. Moss, W. Zareba, and W. Hall Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N. Engl. J. Med. 346 2002 877 883
4. E.F. Philbin, C. Andreou, T.A. Rocco, L.J. Lynch, and S.L. Baker Patterns of angiotensin converting enzyme inhibitor use in congestive heart failure in two community hospitals Am. J. Cardiol. 77 1996 832 838
5. Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology: guidelines for the diagnosis and treatment of chronic heart Failure Eur. Heart J. 22 2001 1527 1560
6. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary J. Am. Coll. Cardiol. 38 2001 2101 2113
7. D. King Diagnosis and management of heart failure in the elderly Postgrad. Med. J. 72 1996 577 580
8. M. Ledwidge, B. Travers, M. Ryder, E. Ryan, and K.M. McDonald Specialist care of heart failure improvers appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions Eur. J. Heart Fail. 6 2004 235 243
9. D.S. Wald, R.S. More, M. Martin, L. Hughes, and C.J. Reid Can beta blockers be safely initiated at home in patients with heart failure? QJM 95 2002 55 56
10. M. Packer, P.A. Poole-Wilson, and P.W. Armstrong Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group Circulation 100 1999 2312 2318
11. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised aldactone evaluation study N. Engl. J. Med. 341 1999 709 717
12. D.N. Juurlink, M.M. Mamdani, D.S. Lee, A. Kopp, P.C. Austin, and Laupacis Rates of hyperkalaemia after publication of the randomised aldactone evaluation study N. Engl. J. Med. 351 2004 543 551
13. J.J.V. McMurray, and E. O'Meara Treatment of heart failure with spironolactone-trial and tribulations N. Engl. J. Med. 351 2004 526 528
14. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N. Engl. J. Med. 348 2003 1309 1321
15. A.J. Moss, W. Zareba, and W.J. Hall Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N. Engl. J. Med. 346 2002 877 883
16. D.M. Bloomfield, R.C. Steinman, P.B. Namerow, M. Parides, J. Davidenko, and E.S. Kaufman Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy Circulation 110 2004 1885 1889
17. P.R. Kalra, J.C. Moon, and A.J. Coats Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure Int. J. Cardiol. 85 2002 195 197
18. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat, and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
19. W.J. Remme, G. Riegger, and P. Hildebrandt The benefits of early combination therapy with carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial Cardiovasc. Drugs Ther. 18 2004 570 576
20. B. Pitt, and F.A. Segal Martinez Randomised trial of losartan versus captopril in patients over 65 with heart failure Lancet 349 1997 747 752
21. D.M. McNamara, R. Holubkov, and K. Janosko Pharmacologic interactions between beta-blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure Circulation 103 2001 1644 1648
22. P. deGroote, N. Helbecque, N. Lamblin, X. Hermant, P. Amouyel, and C. Bauters Beta-adrenergic receptor blockade and the angiotensin-converting enzyme deletion polymorphism in patients with chronic heart failure Eur. J. Heart Fail. 6 2004 17 21
23. D.M. McNamara, R. Holubkov, L. Postava, K. Janosko, G.A. MacGowan, and M. Mathier Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin converting enzyme deletion polymorphism in patients with heart failure J. Am. Coll. Cardiol. 44 2004 2019 2026
24. R.W. Troughton, C.M. Frampton, T.G. Yandle, E.A. Espiner, M.G. Nicholls, and A.M. Richards Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
25. T. Simon, M. Mary-Krause, and C. Funck Brentano Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study (CIBIS II) Eur. Heart J. 24 2003 552 559
26. J. Wikstrand, A. Hjalmarson, and F. Waagstein Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure J. Am. Coll. Cardiol. 40 2002 491 498
27. W.S. Colucci, M. Packer, and M.R. Bristow Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group Circulation 94 1996 2800 2806
28. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitors: the CHARM-Added Trial Lancet 362 2003 767 7671
29. J.N. Cohn, G. Tognoni Valsartan Heart Failure Trial Investigators A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 345 2001 1667 1675
30. A. Ali, A. Walsh, M.T. Ledwidge, E. Ryan, B. Travers, and M. Ryder Multiple neurohumoral blockade in heart failure: are we dropping blood pressure too low? Eur. J. Heart Fail., Suppl. 2 1 2003 150
31. A.L. Taylor, S. Ziesche, C. Yancy, P. Carson, R. D'Agostino, and K. Ferdinand Combination of isosorbide dinitrate and hydralazine in blacks with heart failure N. Engl. J. Med. 351 2004 2049 2057
32. E.F. Lewis, P.A. Johnston, W. Johnston, C. Colins, L. Griffin, and L.W. Stevenson Preferences for quality of life or survival expressed by patients with heart failure J. Heart Lung Transplant. 20 2001 1016 1024
33. S. Stewart, L. Blue, A. Walker, C. Morrison, and J.J. McMurray An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it? Eur. Heart J. 23 2002 1369 1378
34. M. Ledwidge, M. Barry, and J. Cahill Is multidisciplinary care cost beneficial combined with optimal medical care Eur. J. Heart Fail. 5 2003 381 389